Investors monitoring the "TMO stock price forecast" should track FDA approval activity, as regulatory shifts can catalyze product demand and revenue acceleration. Shares of this maker of scientific instrument and laboratory supplies have returned +3.3% over the past month versus the Zacks S&P 500 composite's +5.2% change. The Zacks Medical - Instruments industry, to which Thermo Fisher belongs, has gained 4.9% over this period. Now the key question is: Where could the stock be headed in the near term? To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. Analysts covering the "TMO stock price forecast" point to earnings stability and a robust pipeline of biotech tools, projecting low double-digit revenue growth into FY